,Canonical_Smiles,drug_name,drug_type,Label
0,CC(=O)[C@@]1(C)CC[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]21C,Medrogestone,3A4-Substrate,negative
1,CC(=O)[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,Progesterone,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,positive
2,CO[C@@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,Artemether,2D6-Substrate,negative
3,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
4,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)NC1=O)C(C)C,Insulin (human),Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
5,CON=CC1=CCCN(C)C1,Milameline,2D6-Substrate,negative
6,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,Molindone,2D6-Substrate,negative
7,CCN(CC)CCNC(=O)c1ccc(N)cc1,Procainamide,2D6-Substrate,negative
8,CN1CCC23CCCCC2C1Cc1ccc(O)cc13,Dextrorphan,2D6-Substrate,negative
9,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,Bupivacaine,2D6-Substrate,negative
10,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,Colchicine,2E1-Inducer,negative
11,O=N[O-],Sodium Nitrite,GST-Inhibitor,negative
12,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,positive
13,CCC(C)C(=O)OC1CCC=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,Mevastatin,-,negative
14,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,Sulfadoxine,-,negative
15,C[N+](C)([O-])CCCN1c2ccccc2CCc2ccccc21,Imipramine Oxide,1A2-Substrate,negative
16,CN(C)CC(Oc1ccccc1)Oc1ccccc1,Medifoxamine,-,negative
17,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)[C@@H]1c1cccc([N+](=O)[O-])c1,Nicardipine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,positive
18,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,Amoxicillin,Solute_carrier_family_22_member_6-Substrate,negative
19,O=C(O)c1cc(N=Nc2ccc(O)c(C(=O)O)c2)ccc1O,Olsalazine,Methyltransferase-Inhibitor,negative
20,C=CC[C@]1(O)CC[C@H]2[C@H]3CCC4=CCCC[C@H]4[C@@H]3CC[C@]21C,Allylestrenol,3A4-Substrate,negative
21,COc1ccc2c(CN(C)C)cc(=O)oc2c1,DiMMAMC,2D6-Substrate,negative
22,CCNc1nc(Cl)nc(NC(C)(C)C)n1,terbutylazine,2C19-Substrate,negative
23,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,tolterodine,2D6-Substrate,negative
24,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,Valdecoxib,2D6-Substrate,negative
25,CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,Benzethonium,2D6-Substrate,negative
26,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,Nilotinib,UGT-Inhibitor,negative
27,CCN1C(=O)N[C@@H](c2ccccc2)C1=O,Ethotoin,-,negative
28,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21,Valaciclovir,Solute_carrier_family_15_member_2-Substrate,negative
29,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,Bumetanide,Solute_carrier_family_12_member_2-Inhibitor,negative
30,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,Tamoxifen,19A-Inhibitor,negative
31,C=CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_10,3A4-Substrate,negative
32,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C,Metamizole Sodium,GST-Inducer,negative
33,CN[C@]1(c2ccccc2Cl)CCCCC1=O,Esketamine,2B6-Substrate,negative
34,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],Isosorbide Dinitrate,2E1-Inhibitor,negative
35,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
36,CCN(CC)C(=O)N1CCN(C)CC1,Diethylcarbamazine,GST-Inducer,negative
37,CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,Linezolid,-,negative
38,O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,Flufenamic Acid,2E1-Inducer,negative
39,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,sibutramine,2C19-Substrate,negative
40,CC(C)NC[C@H](O)c1ccc(O)c(O)c1,Isoprenaline,19A-Inducer,negative
41,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Sorbitol,1A2-Inhibitor,negative
42,CC1(C)Cc2c(-c3ccccc3)c(-c3ccc(Cl)cc3)c(CC(=O)O)n2C1,licofelone,2D6-Substrate,negative
43,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)C=CC=CC[C@@H](C)OC(=O)C[C@H]1OC(C)=O,Josamycin,-,negative
44,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)C=C[C@H](C)C(C)C,Ergocalciferol,Arachidonic_acid_epoxygenase-Substrate,negative
45,COc1ccc2[nH]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1,Omeprazole,CP2CI-Substrate,negative
46,COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(=O)O)cc1,TR_14035,2C9-Substrate,negative
47,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,Oxaprozin,2C9-Substrate,negative
48,O=NN1CCCC1,N_nitroso_pyrrolidine,2E1-Substrate,negative
49,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,Chlorphenamine,Methyltransferase-Inducer,negative
50,COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,Trabectedin,2E1-Substrate,negative
51,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,Proguanil,2E1-Substrate,negative
52,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,Pranidipine,-,negative
53,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,Cyproheptadin,UGT-Substrate,negative
54,CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,Pimecrolimus,3A4-Substrate,negative
55,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,Nevirapine,2D6-Substrate,negative
56,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1,Sparteine,2D6-Inhibitor,negative
57,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,Paroxetine,2D6-Inhibitor,negative
58,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,Pemetrexed,Proton_coupled_folate_transporter-Substrate,negative
59,S=P(N1CC1)(N1CC1)N1CC1,Thiotepa,GST-Substrate,negative
60,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,DMZ,2C19-Substrate,negative
61,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,Triclosan,SUL-Inhibitor,negative
62,CN(C)N=Nc1[nH]cnc1C(N)=O,Dacarbazine,2E1-Substrate,negative
63,O=C(CCCCCCC(=O)Nc1ccccc1)NO,Vorinostat,Methyltransferase-Inhibitor,negative
64,O=O,Oxygen,Solute_carrier_family_12_member_2-Inducer,negative
65,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1,Dexfenfluramine,2E1-Inhibitor,negative
66,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,Glibenclamide,-,negative
67,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Alprazolam,P450_HFLA-Substrate,negative
68,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O,androstenedione,3A4-Substrate,negative
69,CCCCCNC(=N)NN=Cc1c[nH]c2ccc(CO)cc12,Tegaserod,2E1-Inhibitor,negative
70,COc1ccc(O)cc1,Mequinol,GST-Inducer,negative
71,C1CCC(C(C[C@H]2CCCCN2)C2CCCCC2)CC1,Perhexiline,2D6-Substrate,negative
72,O=Cc1c2ccccc2cc2ccccc12,9_anthraldehyde,2E1-Substrate,negative
73,C#CCC12CCC(=O)C=C1CCC1C3CCC(=O)C3(C)CCC12,Plomestane,-,negative
74,CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,Delapril,-,negative
75,OCc1cc([C@@H](O)CNCCCCCCOCCCCc2ccccc2)ccc1O,Salmeterol,P450_HFLA-Substrate,negative
76,[Br-],Bromides,Solute_carrier_family_22_member_2-Substrate,negative
77,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Aceclofenac,-,negative
78,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,Cortisol,-,negative
79,Nc1ccccc1,Aniline,-,negative
80,CN(C)CCO[C@@](C)(c1ccccc1)c1ccccn1,Doxylamin,P450_HFLA-Inducer,negative
81,Nc1nc(C(=CCC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@@H]23)cs1,Ceftibuten,Solute_carrier_family_15_member_1-Substrate,negative
82,CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,Tenofovir Disoproxil,2E1-Inhibitor,negative
83,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Methyltestosterone,19A-Inducer,negative
84,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,Diltiazem,P450_HFLA-Substrate,negative
85,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,terbinafine,2C19-Substrate,negative
86,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Lercanidipine,P450_HFLA-Substrate,negative
87,COc1ccc2ccc(=O)oc2c1,7_methoxy_coumarin,2E1-Substrate,negative
88,CC(Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,Tenofovir,-,negative
89,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,Pergolide,2D6-Inhibitor,negative
90,CC(C)(Oc1ccc([C@H]2CC2(Cl)Cl)cc1)C(=O)O,Ciprofibrate,4A11-Inducer,negative
91,CC(NCC(O)COc1cccc2ccccc12)C(C)(C)C,tert_butyl_propranolol,2D6-Substrate,negative
92,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,Ziprasidone,P450_HFLA-Substrate,negative
93,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
94,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,barnidipine,2D6-Substrate,negative
95,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,Anastrozole,19A-Inhibitor,negative
96,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,Ribavirin,Solute_carrier_family_28_member_3-Substrate,negative
97,ClC1=C(Cl)C2(Cl)C3C4CC(C5OC45)C3C1(Cl)C2(Cl)Cl,Dieldrin,-,negative
98,O=c1ccc2ccccc2o1,Coumarin,-,negative
99,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,Letrozole,19A-Inhibitor,negative
100,O=C(O)CCC/C=C\C[C@@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,S_145,2C9-Substrate,negative
101,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,chlorpyrifos,2D6-Substrate,negative
102,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,Cisapride,GST-Inducer,negative
103,Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,Dapsone,CP2CI-Substrate,negative
104,CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,Capravirine,-,negative
105,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](CC=C(C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)C=CC=C3CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2,Ivermectin,-,negative
106,CCN(CC)C(=O)SC,DETC_Me,2E1-Substrate,negative
107,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,progesterone,2D6-Substrate,negative
108,CN[C@@]1(C)[C@H]2CC[C@H](C2)C1(C)C,Mecamylamine,1A1-Inducer,negative
109,c1ccc2[nH]ccc2c1,indole,2E1-Substrate,negative
110,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
111,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,Dofetilide,-,negative
112,C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,SNI_2011_R_R,2D6-Substrate,negative
113,NCCCC(=O)O,Aminobutyric Acid,2D6-Substrate,negative
114,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN[C@H](C)C3)c(F)c21,Lomefloxacin,-,negative
115,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Adriamycin,GST-Substrate,negative
116,CN(C)CCC=C1c2ccccc2COc2ccccc21,Doxepin,GST-Inhibitor,negative
117,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
118,OCCOCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Hydroxyzine,2D6-Inhibitor,negative
119,CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1,rosiglitazone_R,2C9-Substrate,negative
120,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
121,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,Lornoxicam,-,negative
122,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(C=NNO)cc1)C1CCCCC1,Ximelagatran,2C9-Substrate,negative
123,NC(=O)N1C(=O)C(=C(O)c2cccs2)c2cc(Cl)ccc21,Tenidap,Electrogenic_sodium_bicarbonate_cotransporter_1-Inhibitor,negative
124,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,Mosapride,-,negative
125,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,cisapride,2C8-Substrate,negative
126,Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,FLU,2C9-Substrate,negative
127,[Ag],Silver,Probable_low_affinity_copper_uptake_protein_2-Inhibitor,negative
128,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C,deoxycholic_acid,3A4-Substrate,negative
129,CCC(C)(C)NCC(O)COc1ccccc1C(=O)CCc1ccccc1,Diprafenone,2D6-Substrate,negative
130,CCN(CC)CCOC(=O)c1ccc(N)cc1,Procaine,Methyltransferase-Inhibitor,negative
131,NC(=O)c1ccccc1O,Salicylamide,1B1-Inhibitor,negative
132,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,Triamterene,1A2-Inhibitor,negative
133,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,Naproxen,SUL-Inhibitor,negative
134,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,Hydrochlorothiazide,Solute_carrier_family_12_member_1-Inducer,negative
135,NCCS,Mercaptamine,GST-Inhibitor,negative
136,Cc1c2ccncc2c(C)c2c1[nH]c1ccccc12,ellipticine,2D6-Substrate,negative
137,Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C,Sulfamoxole,-,negative
138,CCCC(=O)O,Hydroxybutyric Acid,Monocarboxylate_transporter_1-Substrate,negative
139,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Imatinib,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,positive
140,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,Lynestrenol,2C19-Inducer,negative
141,C=CCOc1ccccc1OC[C@H](O)CNC(C)C,Oxprenolol,2D6-Inhibitor,negative
142,CCN[C@@H]1C[C@H](N)[C@@H](O[C@@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O,Netilmicin,N_acetyltransferase-Substrate,negative
143,C[C@H](C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,Pirprofen,UGT-Substrate,negative
144,CC[C@H](C(N)=O)N1CCCC1=O,Levetiracetam,GST-Inducer,negative
145,O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1,Didanosine,Solute_carrier_family_15_member_1-Substrate,negative
146,COc1ccc2c3c1OC1C(O)C=CC4C(C2)NCCC341,Norcodeine,2D6-Substrate,negative
147,CCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_ethylamphetamine,2D6-Substrate,negative
148,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,Bosentan,Sodiumbile_acid_cotransporter-Inhibitor,negative
149,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,Triazolam,P450_HFLA-Substrate,negative
150,Cn1cnc2c1c(=O)n(CC1CCCO1)c(=O)n2C,theobromine_deriv_9,3A4-Substrate,negative
151,O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,Indoramin,2D6-Substrate,negative
152,c1ccc2c(c1)Sc1ccccc1N2C[C@H]1CN2CCC1CC2,Mequitazine,2D6-Substrate,negative
153,CCCCCCCCCCCCCC(=O)O,myristic_acid,2E1-Substrate,negative
154,CN[C@H](C)Cc1ccccc1,methamphetamine_R,2D6-Substrate,negative
155,O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2ccccc21,Phenolphthalein,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
156,CC(C)(C=O)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_aldehyde_finasteride,3A4-Substrate,negative
157,CC(C(=O)O)c1ccc2c(c1)CC(=O)c1ccccc1S2,Zaltoprofen,-,negative
158,CC(=O)C[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Warfarin,CP2CI-Substrate,negative
159,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,Acetylcarnitine,Solute_carrier_family_22_member_5-Substrate,negative
160,COc1ccc2[nH]c3c([N+](=O)[O-])ccc4c3c(nn4CCCN(C)C)c2c1,pyrazolo_acridine,1A2-Substrate,negative
161,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
162,Nc1nc2c(ncn2COCCO)c(=O)[nH]1,Aciclovir,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
163,COc1ccc(-c2nc3ccc(C4=NNC(=O)CC4C)cc3[nH]2)cc1,Pimobendan,-,negative
164,O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,Fluorescein,Solute_carrier_family_22_member_6-Substrate,negative
165,CCN(CC)C(=O)C(C#N)=Cc1cc(O)c(O)c([N+](=O)[O-])c1,Entacapone,2E1-Inhibitor,negative
166,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,Erlotinib,UGT-Inhibitor,negative
167,COc1ccc(CN2CCNCC2)c(OC)c1OC,Trimetazidine,-,negative
168,CCC[C@@](C)(COC(N)=O)COC(=O)NC(C)C,Carisoprodol,-,negative
169,Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,Cidofovir,Solute_carrier_family_22_member_6-Substrate,negative
170,CCO,Ethanol,4A11-Inducer,negative
171,N[C@H]1C[C@@H]1c1ccccc1,Tranylcypromine,2E1-Inhibitor,negative
172,CCN(CC)c1cc(C)nc2ncnn12,Trapidil,-,negative
173,O=C(O)COc1ccc(C(=O)c2ccsc2)c(Cl)c1Cl,tienilic_acid_deriv_3_isomer,2C9-Substrate,negative
174,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=C[C@H](O)C[C@@H](O)CC(=O)O,Rosuvastatin,Sodiumbile_acid_cotransporter-Substrate,negative
175,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,Prochlorperazine,2D6-Substrate,negative
176,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(C(C)C)cccc2C(C)C)c(C(C)C)c1,Avasimibe,-,negative
177,CC(CF)NCC(O)COc1cccc2ccccc12,fluoro_propranolol,2D6-Substrate,negative
178,Oc1nc2cc(Cl)ccc2o1,Chlorzoxazone,2E1-Inhibitor,negative
179,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,Fingolimod,4F2-Substrate,negative
180,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,Digoxin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
181,NC(N)=NN=Cc1c(Cl)cccc1Cl,Guanabenz,-,negative
182,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
183,CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,Mepacrine,Methyltransferase-Inhibitor,negative
184,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,Colecalciferol,2D6-Inhibitor,negative
185,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,Bezafibrate,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
186,O=c1c(O)c(-c2ccccc2)oc2cc(O)cc(O)c12,galangin,2C9-Substrate,negative
187,CCCCOc1ccc2ccc(=O)oc2c1,7_butoxy_coumarin,3A4-Substrate,negative
188,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,Prazepam,3A4-Substrate,negative
189,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,Resiquimod,-,negative
190,Nc1ccc(Cc2ccc(N)c(Cl)c2)cc1Cl,MOCA,3A4-Substrate,negative
191,CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1,Gepirone,2D6-Substrate,negative
192,O=C1C(CCSc2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,sulfinpyrazone_sulfide,2C9-Substrate,negative
193,CCC(=O)O[C@@H](O[P@@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,Fosinopril,Solute_carrier_family_15_member_2-Substrate,negative
194,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ergometrine,-,negative
195,CC(=O)Oc1ccccc1C(=O)O,Acetylsalicylic Acid,GST-Inducer,negative
196,O=C1OC2(c3ccc(OCc4ccccc4)cc3Oc3cc(OCc4ccccc4)ccc32)c2ccccc21,dibenzyl_fluorescein,2D6-Substrate,negative
197,O=C1c2ccccc2C(=O)c2ccccc21,Anthraquinone,-,negative
198,CCc1ccc([C@@H](C)CCc2ccc([N+](C)(C)C)cc2)cc1,Colestyramine,Sodiumbile_acid_cotransporter-Inducer,negative
199,Clc1ccc(CO[C@@H](C[C@H]2C=NC=N2)c2ccc(Cl)cc2Cl)cc1,Econazole,19A-Inhibitor,negative
200,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,Metoclopramide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
201,CCc1ccccc1,Ethylbenzene,-,negative
202,OC(CNCC(F)(F)F)COc1cccc2ccccc12,N_trifluoro_ethyl_desisopropyl_propranolol,2D6-Substrate,negative
203,OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,Glucose,2E1-Inhibitor,negative
204,CC12C=CC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,Boldenone,-,negative
205,C[C@@H]1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,Argatroban,Methyltransferase-Inducer,negative
206,Cc1c2oc3c(C)ccc(C(=O)N[C@H]4C(=O)N[C@@H](C(C)C)C(=O)N5CCC[C@@H]5C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]4C)c3nc-2c(C(=O)N[C@H]2C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@@H]3C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]2C)c(N)c1=O,Dactinomycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
207,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,Candesartan,-,negative
208,COc1ccc(CCNCCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_R,2C8-Substrate,negative
209,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,Tamsulosin,2D6-Substrate,negative
210,CO[C@@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](O[C@H]3O[C@@H](C)C[C@@H](N(C)C)[C@H]3O)[C@H]2C)O[C@@H](C)[C@H]1O,Oleandomycin,UGT-Substrate,negative
211,CCCN[C@@H]1CCc2nc(N)sc2C1,Pramipexole,-,negative
212,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,Rivastigmine,2D6-Inhibitor,negative
213,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,Vernakalant,2D6-Substrate,negative
214,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,Repaglinide,-,negative
215,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,Olanzapine,GST-Inducer,negative
216,CC(N)Cc1ccccc1,amphetamine,2D6-Substrate,negative
217,C[C@H](N)[C@H](O)c1cccc(O)c1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate,negative
218,CC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@H](C#N)c1cccc(Oc2ccccc2)c1,Cypermethrin,1A2-Substrate,negative
219,CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Adinazolam,-,negative
220,CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,Clofazimine,-,negative
221,C[C@H](CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,Cyamemazine,2C9-Substrate,negative
222,Cc1c2ccccc2c(C)c2c1ccc1ccccc12,DMBA,2E1-Substrate,negative
223,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
224,CCOc1ccc2cc(C#N)c(=O)oc2c1,3_cyano_7_ethoxycoumarin,2E1-Substrate,negative
225,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1,Bromazepam,2E1-Inhibitor,negative
226,Cc1cc2ccccc2c2ccc3ccccc3c12,5_methylchrysene,2E1-Substrate,negative
227,CCC(C)(C)OC,tert_amyl_methyl_ether,2E1-Substrate,negative
228,COc1ccc2[n-]c(S(=O)Cc3ncc(C)c(OC)c3C)nc2c1,Esomeprazole,2C19-Substrate,negative
